New developments in the area of factor XIII

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 2, 2013, Pages 234-244

  Schroeder, V ^a   Kohler, H P ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b Spital Netz Bern   (Switzerland)

Author keywords

Bone metabolism; Coagulation; Factor XIII; Inflammation; Transglutaminase; Wound healing

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 13; FIBRIN; FIBRINOGEN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

ANGIOGENESIS; ATHEROSCLEROSIS; BLEEDING; BLOOD LEVEL; BONE DISEASE; BONE METABOLISM; BONE MINERALIZATION; CARDIOVASCULAR DISEASE; CHROMOSOME 1; COMPLEMENT ACTIVATION; CONGENITAL BLOOD CLOTTING DISORDER; CROHN DISEASE; DIABETES MELLITUS; ENTERITIS; EXON; EXTRACELLULAR MATRIX; FIBRIN FORMATION; GENE CLUSTER; GENE MUTATION; HEMOPHILIA A; HEMORRHAGIC SHOCK; HEMOSTASIS; HUMAN; IMMUNITY; INFLAMMATION; INJURY; INSULIN RESISTANCE; LACRIMAL FLUID; LIVER REGENERATION; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTIC NERVE; OSTEOARTHRITIS; PREGNANCY DISORDER; PRIORITY JOURNAL; PROTEIN CROSS LINKING; REVIEW; SPONTANEOUS ABORTION; SUBSTITUTION THERAPY; SURGERY; THROMBOSIS; TISSUE REPAIR; WOUND HEALING;

ANIMALS; BLOOD COAGULATION; COAGULANTS; FACTOR XIII; FACTOR XIII DEFICIENCY; HUMANS; MODELS, MOLECULAR; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84873543245     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12074     Document Type: Review

References (112)

1. Kohler HP, Stickland MH, Ossei-Gerning N, Carter AM, Mikkola H, Grant PJ. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost 1998; 79: 8-13.
2. Kohler HP, Futers TS, Grant PJ. Prevalence of three common polymorphisms in the A-subunit gene of FXIII in patients with coronary artery disease. Association with FXIII activity and antigen levels. Thromb Haemost 1999; 81: 511-5.
3. Catto AJ, Kohler HP, Bannen S, Stickland MH, Carter AM, Grant PJ. Factor XIII gene Val34Leu polymorphism: a novel association with primary intracerebral haemorrhage. Stroke 1998; 29: 813-6.
4. Catto AJ, Kohler HP, Coore J, Mansfield MW, Stickland MH, Grant PJ. Association of a common polymorphism in the factor XIII gene with venous thrombosis. Blood 1999; 93: 906-8.
5. Ichinose A. Extracellular transglutaminase: factor XIII. Prog Exp Tumor Res 2005; 38: 192-208.
6. Schroeder V, Vuissoz JM, Caflisch A, Kohler HP. Factor XIII activation peptide is released into plasma upon cleavage by thrombin and shows a different structure compared to its bound form. Thromb Haemost 2007; 97: 890-8.
7. Yee VC, Pedersen LC, Bishop PD, Stenkamp RE, Teller DC. Structural evidence that the activation peptide is not released upon thrombin cleavage of factor XIII. Thromb Res 1995; 78: 389-97.
8. Yorifuji H, Anderson K, Lynch GW, van de Water L, McDonagh J. B protein of factor XIII: differentiation between free B and complexed B. Blood 1988; 72: 1645-50.
9. Schroeder V, Durrer D, Meili E, Schubiger G, Kohler HP. Congenital factor XIII deficiency in Switzerland. Swiss Med Wkly 2007; 137: 272-8.
10. Lord ST. Molecular mechanisms affecting fibrin structure and stability. Arterioscler Thromb Vasc Biol 2011; 31: 494-9.
11. 2-antiplasmin cross-linking. Blood 2011; 117: 6371-4.
12. Muszbek L, Bereckzky Z, Bagoly Z, Komáromi I, Katona É. Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev 2011; 91: 931-72.
13. Biswas A, Ivaskevicius V, Seitz R, Thomas A, Oldenburg J. An update of the mutation profile of factor 13 A and B genes. Blood Rev 2011; 25: 193-204.
14. Ivaskevicius V, Biswas A, Thomas A, Schroeder V, Kohler HP, Huetker S, Petrides PE, Oldenburg J. Identification of two novel missense mutations in F13A gene affecting thrombin cleavage site (Arg37) of factor XIII A-subunit. Hämostaseologie 2012; 32: A22 [abstract ED20-5].
15. Perez DL, Diamond EL, Castro CM, Diaz A, Buonanno F, Nogueira RG, Sheth K. Factor XIII deficiency related recurrent spontaneous intracerebral hemorrhage: a case and literature review. Clin Neurol Neurosurg 2011; 113: 142-5.
16. Kohler HP, Ichinose A, Seitz R, Ariens RAS, Muszbek L. Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost 2011; 9: 1404-6.
17. Inbal A, Oldenburg J, Carcao M, Rosholm A, Tehranchi R, Nugent D. Recombinant factor XIII. Blood 2012; 119: 5111-7.
18. Kohler HP. Novel treatment for congenital FXIII deficiency. Blood 2012; 119: 5060-1.
19. Ivaskevicius V, Biswas A, Bevans C, Schroeder V, Kohler HP, Rott H, Halimeh S, Petrides PE, Lenk H, Krause M, Miterski B, Harbrecht U, Oldenburg J. Identification of eight novel coagulation factor XIII subunit A mutations: implied consequences for structure and function. Haematologica 2010; 95: 956-62.
20. Ichinose A. Hemorrhagic acquired factor XIII (13) deficiency and acquired hemorrhaphilia 13 revisited. Semin Thromb Hemost 2011; 37: 382-8.
21. Ichinose A, Souri M. As many as 12 cases with haemorrhagic acquired factor XIII deficiency due to its inhibitors were recently found in Japan. Thromb Haemost 2011; 105: 925-7.
22. Inbal A, Muszbek L. Coagulation factor deficiencies and pregnancy loss. Semin Thromb Hemost 2003; 29: 171-4.
23. Ichinose A, Asahina T, Kobayashi T. Congenital blood coagulation factor XIII deficiency and perinatal management. Curr Drug Targets 2005; 6: 541-9.
24. Asahina T, Kobayashi T, Okada Y, Goto J, Terao T. Maternal blood coagulation factor XIII is associated with the development of cytotrophoblastic shell. Placenta 2000; 21: 388-93.
25. Ogasawara MS, Aoki K, Katano K, Ozaki Y, Suzumori K. Factor XII but not protein C, protein S, antithrombin III, or factor XIII is a predictor of recurrent miscarriage. Fertil Steril 2001; 75: 916-9.
26. Pasquier E, De Saint Martin L, Kohler HP, Schroeder V. Factor XIII plasma levels in women with unexplained recurrent pregnancy loss. J Thromb Haemost 2012; 10: 723-5.
27. Nahrendorf M, Aikawa E, Figueiredo JF, Stangenberg L, van den Borne SW, Blankesteijn WM, Sosnovik DE, Jaffer FA, Tung CH, Weissleder R. Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodelling: implications for FXIII therapy and antithrombin use in myocardial infarction. Eur Heart J 2008; 29: 445-54.
28. Nahrendorf M, Weissleder R, Ertl G. Does FXIII deficiency impair wound healing after myocardial infarction?PLoS ONE 2006; 1: e48.
29. Nahrendorf M, Hu K, Frantz S, Jaffer FA, Tung CH, Hiller KH, Voll S, Nordbeck P, Sosnovik D, Gattenlöhner S, Novikov M, Dickneite G, Reed GL, Jakob P, Rosenzweig A, Bauer WR, Weissleder R, Ertl G. Factor XIII deficiency causes cardiac rupture, impairs wound healing, and aggravates cardiac remodeling in mice with myocardial infarction. Circulation 2006; 113: 1196-202.
30. Sane DC, Kontos JL, Greenberg CS. Roles of transglutaminases in cardiac and vascular diseases. Front Biosci 2009; 12: 2530-45.
31. Noll T, Wozniak G, McCarson K, Hajimohammad A, Metzner HJ, Inserte J, Kummer W, Hehrlein FW, Piper HM. Effect of factor XIII on endothelial barrier function. J Exp Med 1999; 189: 1373-82.
32. Wozniak G, Noll T, Akinturk H, Thul J, Muller M. Factor XIII prevents development of myocardial edema in children undergoing surgery for congenital heart disease. Ann N Y Acad Sci 2001; 936: 617-20.
33. AbdAlla S, Lother H, Langer A, el Faramawy Y, Quitterer U. Factor XIIIA transglutaminase crosslinks AT1 receptor dimers of monocytes at the onset of atherosclerosis. Cell 2004; 119: 343-54.
34. Dardik R, Solomon A, Loscalzo J, Eskaraev R, Bialik A, Goldberg I, Schiby G, Inbal A. Novel proangiogenic effect of factor XIII associated with suppression of thrombospondin 1 expression. Arterioscler Thromb Vasc Biol 2003; 23: 1472-7.
35. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 2002; 6: 1-12.
36. Nor JE, Mitra RS, Sutorik MM, Mooney DJ, Castle VP, Polverini PJ. Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway. J Vasc Res 2000; 37: 209-18.
37. Dardik R, Leor J, Skutelsky E, Castel D, Holbova R, Schiby G, Shaish A, Dickneite G, Loscalzo J, Inbal A. Evaluation of the pro-angiogenic effect of factor XIII in heterotopic mouse heart allografts and FXIII-deficient mice. Thromb Haemost 2006; 95: 546-50.
38. Kilian O, Fuhrmann R, Alt V, Noll T, Coskun S, Dingeldein E, Schnettler R, Franke RP. Plasma transglutaminase factor XIII induces microvessel ingrowth into biodegradable hydroxyapatite implants in rats. Biomaterials 2005; 26: 1819-27.
39. Dallabrida SM, Falls LA, Farrell DH. FXIIIa supports microvascular endothelial cell adhesion and inhibits capillary tube formation in fibrin. Blood 2000; 95: 2586-92.
40. Dardik R, Loscalzo J, Inbal A. Factor XIII (FXIII) and angiogenesis. J Thromb Haemost 2006; 4: 19-25.
41. Dardik R, Loscalzo J, Eskaraev R, Inbal A. Molecular mechanisms underlying the proangiogenic effect of factor XIII. Arterioscler Thromb Vasc Biol 2005; 25: 526-32.
42. Raggatt LJ, Partridge NC. Cellular and molecular mechanisms of bone remodelling. J Biol Chem 2010; 285: 25103-8.
43. Huang W, Yang S, Shao J, Li YP. Signaling and transcriptional regulation in osteoblast commitment and differentiation. Front Biosci 2007; 12: 3068-92.
44. Aeschlimann D, Mosher D, Paulsson M. Tissue transglutaminase and factor XIII in cartilage and bone remodeling. Semin Thromb Hemost 1996; 22: 437-43.
45. Aeschlimann D, Thomazy V. Protein crosslinking in assembly and remodelling of extracellular matrices: the role of transglutaminases. Connect Tissue Res 2000; 41: 1-27.
46. Aeschlimann D, Wetterwald A, Fleisch H, Paulsson M. Expression of tissue transglutaminase in skeletal tissues correlates with events of terminal differentiation of chondrocytes. J Cell Biol 1993; 120: 1461-70.
47. De Laurenzi V, Melino G. Gene disruption of tissue transglutaminase. Mol Cell Biol 2001; 21: 148-55.
48. Nakano Y, Al-Jallad HF, Mousa A, Kaartinen MT. Expression and localization of plasma transglutaminase factor XIIIA in bone. J Histochem Cytochem 2007; 55: 675-85.
49. Al-Jallad HF, Myneni VD, Piercy-Kotb SA, Chabot N, Mulani A, Keillor JW, Kaartinen MT. Plasma membrane factor XIIIA transglutaminase activity regulates osteoblast matrix secretion and deposition by affecting microtubule dynamics. PLoS ONE 2011; 6: e15893.
50. Al-Jallad HF, Nakano Y, Chen JLY, McMillan E, Lefebvre C, Kaartinen MT. Transglutaminase activity regulates osteoblast differentiation and matrix mineralization in MC3T3-E1 osteoblast cultures. Matrix Biol 2006; 25: 135-48.
51. Piercy-Kotb SA, Mousa A, Al-Jallad HF, Myneni VD, Chicatun F, Nazhat SN, Kaartinen MT. Factor XIIIA transglutaminase expression and secretion by osteoblasts is regulated by extracellular matrix collagen and the MAP kinase signaling pathway. J Cell Physiol 2012; 227: 2936-46.
52. Sanchez C, Deberg MA, Bellahcène A, Castronovo V, Msika P, Delcour JP, Crielaard JM, Henrotin YE. Phenotypic characterization of osteoblasts from the sclerotic zones of osteoarthritic subchondral bone. Arthritis Rheum 2008; 58: 442-55.
53. Floccard B, Rugeri L, Faure A, Denis MS, Boyle EM, Peguet O, Levrat A, Guillaume C, Marcotte G, Vulliez A, Hautin E, David JS, Negrier C, Allaouchiche B. Early coagulopathy in trauma patients: an on-scene and hospital admission study. Injury 2012; 43: 26-32.
54. Hess JR, Brohi K, Dutton RP, Hauser CJ, Holcomb JB, Kluger Y, Mackway-Jones K, Parr MJ, Rizoli SB, Yukioka T, Hoyt DB, Bouillon B. The coagulopathy of trauma: a review of mechanisms. J Trauma 2008; 65: 748-54.
55. Johansson PI, Stissing T, Bochsen L, Ostrowski SR. Thrombelastography and tromboelastometry in assessing coagulopathy in trauma. Scand J Trauma Resusc Emerg Med 2009; 17: 45.
56. Levrat A, Gros A, Rugeri L, Inaba K, Floccard B, Negrier C, David JS. Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients. Br J Anaesth 2008; 100: 792-7.
57. Leemann H, Lustenberger T, Talving P, Kobayashi L, Bukur M, Brenni M, Bruesch M, Spahn DR, Keel MJ. The role of rotation thromboelastometry in early prediction of massive transfusion. J Trauma 2010; 69: 1403-9.
58. Schroeder V, Kohler HP. Thrombelastographic studies on factor XIII. Thromb Haemost 2010; 104: 1277-9.
59. Gerlach R, Tolle F, Raabe A, Zimmermann M, Siegemund A, Seifert V. Increased risk for postoperative hemorrhage after intracranial surgery in patients with decreased factor XIII activity: implications of a prospective study. Stroke 2002; 33: 1618-23.
60. Wettstein P, Haeberli A, Stutz M, Rohner M, Corbetta C, Gabi K, Schnider T, Korte W. Decreased factor XIII availability for thrombin and early loss of clot firmness in patients with unexplained intraoperative bleeding. Anesth Analg 2004; 99: 1564-9.
61. Korte W. FXIII in preoperative coagulation management. Best Pract Res Clin Anaesthesiol 2010; 24: 85-93.
62. Gerlach R, Raabe A, Zimmermann M, Siegemund A, Seifert V. Factor XIII deficiency and postoperative hemorrhage after neurosurgical procedures. Surg Neurol 2000; 54: 260-4.
63. Johansson PI, Sørensen AM, Perner A, Welling KL, Wanscher M, Larsen CF, Ostrowski SR. Disseminated intravascular coagulation or acute coagulopathy of trauma shock early after trauma? An observational study. Crit Care 2011; 15: R272.
64. Zaets SB, Xu DZ, Lu Q, Feketova E, Berezina TL, Malinina IV, Deitch EA, Olsen EH. Recombinant factor XIII mitigates hemorrhagic shock-induced organ dysfunction. J Surg Res 2011; 166: e135-42.
65. Dunn EJ, Grant PJ. Type 2 diabetes: an atherothrombotic syndrome. Curr Mol Med 2005; 5: 323-32.
66. Kohler HP. Insulin resistance syndrome: interaction with coagulation and fibrinolysis. Swiss Med Wkly 2002; 132: 241-52.
67. Kohler HP, Grant PJ. Plasminogen activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342: 1792-801.
68. Mansfield MW, Kohler HP, Ariëns RAS, Grant PJ. Circulating levels of coagulation factor XIII in subjects with type II diabetes mellitus and their first degree relatives. Diabetes Care 2000; 23: 703-5.
69. Opal SM. Phylogenetic and functional relationships between coagulation and the innate immune response. Crit Care Med 2000; 28: S77-80.
70. Ichinose A. Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control. Int J Hematol 2012; 95: 362-70.
71. Loof TG, Mörgelin M, Johansson L, Oehmcke S, Olin AI, Dickneite G, Norrby-Teglund A, Theopold U, Herwald H. Coagulation, an ancestral serine protease cascade, exerts a novel function in early immune defense. Blood 2011; 118: 2589-98.
72. Birnbaum J, Hein OV, Lührs C, Rückbeil O, Spies C, Ziemer S, Gründling M, Usichenko T, Meissner K, Pavlovic D, Kox WJ, Lehmann C. Effects of coagulation factor XIII on intestinal functional capillary density, leukocyte adherence and mesenteric plasma extravasation in experimental endotoxemia. Crit Care 2006; 10: R29.
73. Lee SY, Chang SK, Lee IH, Kim YM, Chung SI. Depletion of plasma factor XIII prevents disseminated intravasular coagulation-induced organ damage. Thromb Haemost 2001; 85: 464-9.
74. Howes JM, Richardson VR, Smith KA, Schroeder V, Somani R, Shore A, Hess K, Ajjan R, Pease RJ, Keen JN, Standeven KF, Carter AM. Complement C3 is a novel plasma clot component with anti-fibrinolytic properties. Diab Vasc Dis Res 2012; 9: 216-25.
75. Hess K, Alzahrani SH, Mathai M, Schroeder V, Carter AM, Howell G, Koko T, Strachan MW, Price JF, Smith KA, Grant PJ, Ajjan RA. A novel mechanism for hypofibrinolysis in diabetes: the role of complement C3. Diabetologia 2012; 55: 1103-13.
76. Richardson VR, Schroeder V, Grant PJ, Standeven KF, Carter AM. Complement C3 is a substrate for activated factor XIII that is cross-linked to fibrin during clot formation. Br J Haematol 2012; 160: 116-9.
77. Nikolajsen CL, Scavenius C, Enghild JJ. Human complement C3 is a substrate for transglutaminases. A functional link between non-protease-based members of the coagulation and complement cascades. Biochemistry 2012; 51: 4735-42.
78. Hess K, Ajjan R, Phoenix F, Dobó J, Gál P, Schroeder V. Effects of MASP-1 of the complement system on activation of coagulation factors and plasma clot formation. PLoS ONE 2012; 7: e35690.
79. Bagoly Z, Katona E, Muszbek L. Factor XIII and inflammatory cells. Thromb Res 2012; 129: S77-81.
80. Cordell PA, Kile BT, Standeven KF, Josefsson EC, Pease RJ, Grant PJ. Association of coagulation factor XIII-A with Golgi proteins within monocyte-macrophage: implications for subcellular trafficking and secretion. Blood 2010; 115: 2674-81.
81. Kovar FM, Marsik CL, Jilma B, Mannhalter C, Joukhadar C, Wagner OF, Endler G. The inflammatory response is influenced by FXIII Val34Leu polymorphism in a human LPS model. Wien Klin Wochenschr 2009; 121: 515-9.
82. Cougard PA, Desjeux A, Vitton V, Baumstarck-Barrau K, Lesavre N, Grimaud JC. The usefulness of factor XIII levels in Crohn's disease. J Crohns Colitis 2012; 6: 660-4.
83. Hayat M, Ariëns RA, Moayyedi P, Grant PJ, O'Mahony S. Coagulation factor XIII and markers of thrombin generation and fibrinolysis in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002; 14: 249-56.
84. Higaki S, Nakano K, Onaka S, Amano A, Tanioka Y, Harada K, Hashimoto S, Sakaida I, Okita K. Clinical significance of measuring blood coagulation factor XIIIA regularly and continuously in patients with Crohn's disease. J Gastroenterol Hepatol 2006; 21: 1407-11.
85. D'Argenio G, Calvani M, Della Valle N, Cosenza V, Di Matteo G, Giorgio P, Margarucci S, Petillo O, Jori FP, Galderisi U, Peluso G. Differential expression of multiple transglutaminases in human colon: impaired keratinocyte transglutaminase expression in ulcerative colitis. Gut 2005; 54: 496-502.
86. Lorenz R, Olbert P, Born P. Factor XIII in chronic inflammatory bowel diseases. Semin Thromb Hemost 1996; 22: 451-5.
87. Bregenzer N, Caesar I, Andus T, Hämling J, Malchoww H, Schreiber S, Schölmerich J. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. The Factor XIII Study Group. Z Gastroenterol 1999; 37: 999-1004.
88. Pihusch R, Salat C, Göhring P, Hentrich M, Wegner H, Pihusch M, Hiller E, Kolb HJ, Ostermann H. Factor XIII activity levels in patients with allogeneic haematopoietic stem cell transplantation and acute graft-versus-host disease of the gut. Br J Haematol 2002; 117: 469-76.
89. Grothaus-Pinke B, Günzelmann S, Fauser AA, Kiehl MG. Factor XIII replacement in stem cell transplant (SCT) recipients with severe graft-versus-host disease of the bowel: report of an initial experience. Transplantation 2001; 72: 1456-8.
90. Kiss F, Simon A, Csáthy L, Hevessy Z, Katona E, Kiss C, Kappelmayer J. A coagulation factor becomes useful in the study of acute leukemias: studies with blood coagulation factor XIII. Cytometry A 2008; 73: 194-201.
91. Kappelmayer J, Simon A, Katona E, Szanto A, Nagy L, Kiss A, Kiss C, Muszbek L. Coagulation factor XIII-A. A flow cytometric intracellular marker in the classification of acute myeloid leukemias. Thromb Haemost 2005; 94: 454-9.
92. Simon A, Bagoly Z, Hevessy Z, Csáthy L, Katona E, Vereb G, Ujfalusi A, Szerafin L, Muszbek L, Kappelmayer J. Expression of coagulation factor XIII subunit A in acute promyelocytic leukemia. Cytometry B Clin Cytom 2012; 82: 209-16.
93. Kiss F, Hevessy Z, Veszprémi A, Katona E, Kiss C, Vereb G, Muszbek L, Kappelmayer JN. Leukemic lymphoblasts, a novel expression site of coagulation factor XIII subunit A. Thromb Haemost 2006; 96: 176-82.
94. Funato M, Kaneko H, Kubota K, Ozeki M, Kanda K, Orii K, Kato Z, Fukao T, Kondo N. Pediatric acute lymphoblastic leukemia mimicking Henoch-Schönlein purpura. Pediatr Int 2011; 53: 766-8.
95. Gonçalves E, Lopes da Silva R, Varandas J, Diniz MJ. Acute promyelocytic leukaemia associated factor XIII deficiency presenting as retro-bulbar haematoma. Thromb Res 2012; 129: 810-1.
96. Quatresooz P, Paquet P, Hermanns-Lê T, Piérard GE. Molecular mapping of factor XIIIa-enriched dendrocytes in the skin. Int J Mol Med 2008; 22: 403-9.
97. Abenoza P, Lillemoe T. CD34 and factor XIIIa in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans. Am J Dermatopathol 1993; 15: 429-34.
98. Goldblum JR, Tuthill RJ. CD34 and factor XIIIa immunoreactivity in dermatofibrosarcoma protuberans and dermatofibroma. Am J Dermatopathol 1997; 19: 147-53.
99. Fusconi M, Ciofalo A, Greco A, Pulice G, Macci M, Mariotti M, Della Rocca C. Solitary fibrous tumor of the oral cavity: case report and pathologic consideration. J Oral Maxillofac Surg 2008; 66: 530-4.
100. Vairaktaris E, Vassiliou S, Yapijakis C, Spyridonidou S, Vylliotis A, Derka S, Nkenke E, Fourtounis G, Neukam FW, Patsouris E. Increased risk for oral cancer is associated with coagulation factor XIII but not with factor XII. Oncol Rep 2007; 18: 1537-43.
101. Jiang WG, Ablin R, Douglas-Jones A, Mansel RE. Expression of transglutaminases in human breast cancer and their possible clinical significance. Oncol Rep 2003; 10: 2039-44.
102. Palumbo JS, Barney KA, Blevins EA, Shaw MA, Mishra A, Flick MJ, Kombrinck KW, Talmage KE, Souri M, Ichinose A, Degen JL. Factor XIII transglutaminase supports hematogenous tumor cell metastasis through a mechanism dependent on natural killer cell function. J Thromb Haemost 2008; 6: 812-9.
103. Orosz ZZ, Katona E, Facskó A, Berta A, Muszbek L. A highly sensitive chemiluminescence immunoassay for the measurement of coagulation factor XIII subunits and their complex in tears. J Immunol Methods 2010; 353: 87-92.
104. Orosz ZZ, Katona E, Facskó A, Módis L, Muszbek L, Berta A. Factor XIII subunits in human tears; their highly elevated levels following penetrating keratoplasty. Clin Chim Acta 2011; 412: 271-6.
105. Sugitani K, Ogai K, Hitomi K, Nakamura-Yonehara K, Shintani T, Noda M, Koriyama Y, Tanii H, Matsukawa T, Kato S. A distinct effect of transient and sustained upregulation of cellular factor XIII in the goldfish retina and optic nerve on optic nerve regeneration. Neurochem Int 2012; 61: 423-32.
106. Tsujimoto I, Moriya K, Sakai K, Dickneite G, Sakai T. Critical role of factor XIII in the initial stages of carbon tetrachloride-induced adult liver remodeling. Am J Pathol 2011; 179: 3011-9.
107. Krushkal J, Bat O, Gigli I. Evolutionary relationships among proteins encoded by the regulator of complement activation gene cluster. Mol Biol Evol 2000; 17: 1718-30.
108. Kerényi A, Pénzes K, Haramura G, Muszbek L. Factor XIII B subunit, a S.aureus protein A binding protein. Abstract presented at the XXIInd International Fibrinogen Workshop, Brighton (UK), July 4-6 2012.
109. Ortner E, Schroeder V, Walser R, Zerbe O, Kohler HP. Sensitive and selective detection of free FXIII activation peptide: a potential marker of acute thrombotic events. Blood 2010; 115: 5089-96.
110. Schroeder V, Ortner E, Mono ML, Galimanis A, Meier N, Findling O, Fischer U, Brekenfeld C, Arnold M, Mattle HP, Kohler HP. Coagulation factor XIII activation peptide and subunit levels in patients with acute ischemic stroke: a pilot study. Thromb Res 2010; 126: e122-7.
111. Schroeder V, Kohler HP. Factor XIII activation peptide - a novel competitive thrombin inhibitor?J Thromb Haemost 2011; 9(Suppl. 2): 376 [abstract P-TU-215].
112. Durrer D. Der congenitale Faktor XIII-Mangel. Eine Darstellung anhand eines Familien-Reports, genealogischer Recherchen und einer kritischen Sichtung der aktualisierten Literatur. Inaugural-Dissertation, University of Zurich, 1999 [MD thesis in German].